Cellectar Biosciences
CLRB
43 hedge funds and large institutions have $14.9M invested in Cellectar Biosciences in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 10 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
0.02% less ownership
Funds ownership: 0.1% → 0.08% (-0.02%)
2% less funds holding
Funds holding: 44 → 43 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
39% less capital invested
Capital invested by funds: $24.2M → $14.9M (-$9.35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$334K |
| 2 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$265K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$221K |
| 4 |
State Street
Boston,
Massachusetts
|
+$214K |
| 5 |
QI
QS Investors
New York
|
+$206K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$3.52M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$976K |
| 3 |
Two Sigma Investments
New York
|
-$588K |
| 4 |
Two Sigma Advisers
New York
|
-$425K |
| 5 |
Millennium Management
New York
|
-$397K |
CLRB Hedge Fund Activity: Q2 2021 in Review
43 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2021, worth a combined $14.9M — down 39% from $24.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CLRB and 9 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 16 added.
The largest buyer was Vanguard Group, adding an estimated $334K. The largest seller was Sio Capital Management, exiting entirely with an estimated $3.52M sold.
- 43 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2021, down from 44 in Q1 2021.
- Funds reported $14.9M of Cellectar Biosciences stock for Q2 2021, down 39% quarter-over-quarter.
- 9 funds opened new Cellectar Biosciences positions in Q2 2021 and 10 closed out, a net change of -1 holder.
- The largest Cellectar Biosciences buyer in Q2 2021 was Vanguard Group, an estimated $334K added.
- The largest Cellectar Biosciences seller in Q2 2021 was Sio Capital Management, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2021.